• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

作者信息

Harrington Patrick, Doores Katie J, Saunders Jamie, de Lord Marc, Saha Chandan, Lechmere Thomas, Khan Hataf, Lam Ho Pui Jeff, Reilly Amy O', Woodley Claire, Asirvatham Susan, Dillon Richard, Curto-Garcia Natalia, Sullivan Jennifer O', Kordasti Shahram, Raj Kavita, Malim Michael H, Radia Deepti, McLornan Donal, Harrison Claire, de Lavallade Hugues

机构信息

Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

School of Cancer and Pharmaceutical Science, King's College London, London, UK.

出版信息

Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.

DOI:10.1038/s41408-022-00651-3
PMID:35459222
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9024068/
Abstract
摘要

相似文献

1
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.接受鲁索替尼治疗的慢性骨髓增殖性肿瘤患者对SARS-CoV-2疫苗接种的体液和T细胞反应受损。
Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.
2
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者对第一剂SARS-CoV-2疫苗接种反应受损。
Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.
3
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.芦可替尼不会损害骨髓纤维化患者对BNT162b2 mRNA新冠疫苗接种的体液免疫反应。
Ann Hematol. 2022 Apr;101(4):929-931. doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24.
4
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.mRNA SARS-CoV-2 疫苗的第三剂加强了骨髓纤维化患者的刺突特异性抗体和记忆 B 细胞反应。
Front Immunol. 2022 Sep 29;13:1017863. doi: 10.3389/fimmu.2022.1017863. eCollection 2022.
5
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.骨髓增殖性肿瘤（MPN）患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的长期反应：芦可替尼的作用和疾病严重程度
Leuk Res. 2022 May;116:106819. doi: 10.1016/j.leukres.2022.106819. Epub 2022 Mar 3.
6
Response to: Ruxolitinib withdrawal due to the COVID-19.对：因 COVID-19 停用鲁索替尼的回应。
Leukemia. 2021 Apr;35(4):1219. doi: 10.1038/s41375-021-01187-4. Epub 2021 Feb 25.
7
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients.骨髓增殖性肿瘤患者对SARS-CoV-2疫苗接种的抗体和T细胞反应。
Leukemia. 2022 Apr;36(4):1176-1179. doi: 10.1038/s41375-022-01533-0. Epub 2022 Feb 25.
8
IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report.鲁索替尼治疗的艾卡迪-古铁雷斯综合征患者在感染新型冠状病毒期间的α干扰素水平：一例报告
Clin Immunol. 2021 Jun;227:108743. doi: 10.1016/j.clim.2021.108743. Epub 2021 Apr 28.
9
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.对未接受机械通气的新型冠状病毒肺炎患者同情用药鲁索替尼：对炎症和通气的短期影响
Clin Transl Sci. 2021 May;14(3):1062-1068. doi: 10.1111/cts.12971. Epub 2021 Jan 27.
10
Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.芦可替尼治疗新型冠状病毒肺炎的过度炎症反应及血液系统恶性肿瘤
Acta Haematol. 2021;144(3):246-249. doi: 10.1159/000510770. Epub 2020 Aug 20.

引用本文的文献

1
Immune profiling of responses to influenza vaccination in patients with myeloproliferative neoplasms.骨髓增殖性肿瘤患者对流感疫苗接种反应的免疫谱分析。
EJHaem. 2024 Apr 11;5(3):573-577. doi: 10.1002/jha2.868. eCollection 2024 Jun.
2
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.鲁索替尼治疗的骨髓纤维化患者发生播散性组织胞浆菌病：一例报告及鲁索替尼相关侵袭性真菌感染的文献综述
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
3
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.

本文引用的文献

1
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的重复疫苗接种在异基因干细胞移植受者中引发强大的多功能T细胞反应。
Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12.
2
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者对第一剂SARS-CoV-2疫苗接种反应受损。
Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.
3
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
使用BBIBP-CorV、AZD1222或BNT162b2疫苗完成针对SARS-CoV-2的疫苗接种方案后，血液系统疾病中体液免疫和细胞免疫反应的比较。
Front Med (Lausanne). 2023 Jul 17;10:1176168. doi: 10.3389/fmed.2023.1176168. eCollection 2023.
4
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
5
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗可增强慢性髓系疾病患者对奥密克戎变异株的中和作用。
Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375.
芦可替尼不会损害骨髓纤维化患者对BNT162b2 mRNA新冠疫苗接种的体液免疫反应。
Ann Hematol. 2022 Apr;101(4):929-931. doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.慢性髓系肿瘤患者对新冠病毒疫苗接种的抗体反应受损。
Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.
6
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.一剂 BNT162b2 mRNA 疫苗可诱导慢性髓性白血病患者产生针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体和多功能 T 细胞反应。
Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.
7
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.单剂量BNT162b2 mRNA新冠疫苗可在骨髓增殖性肿瘤患者中诱导出高频率的中和抗体及多功能T细胞反应。
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
8
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.慢性髓性白血病患者对 TKI 有深度分子反应，恢复了免疫效应物，降低了 PD-1 和免疫抑制剂。
Blood. 2017 Mar 2;129(9):1166-1176. doi: 10.1182/blood-2016-10-745992. Epub 2017 Jan 3.
9
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.JAK抑制可导致辅助性T细胞细胞因子分泌沉默，并使调节性T细胞显著减少。
Br J Haematol. 2015 Oct;171(1):60-73. doi: 10.1111/bjh.13519. Epub 2015 Jun 15.
10
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.JAK 抑制会损害骨髓增殖性肿瘤中的 NK 细胞功能。
Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.